MEFV

Across TCGA pan-cancer cohorts, MEFV Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated MEFV data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher MEFV Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MEFV expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

CESC, READ, and STAD are the cancer types where MEFV Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	III,IV	0.091	0.755	<.001	30	view →
READ	DFS	Median	II,III,IV	0.059	0.818	<.001	28	view →
STAD	OS	Median	All	1.000	0.403	.019	18	view →
BRCA	OS	Median	III,IV	0.211	0.833	<.001	12	view →
UCEC	DFS	Median	All	0.975	0.827	.012	10	view →
THCA	DFS	Median	All	0.091	0.841	<.001	6	view →
SARC	DFS	Median	All	0.186	0.616	.001	6	view →
PRAD	DFS	Median	All	0.617	0.886	.045	6	view →
BLCA	OS	Median	IV	0.051	0.600	<.001	6	view →
ACC	OS	Median	All	0.147	0.685	.018	6	view →
SKCM	DFS	Median	II,III,IV	0.799	0.529	.010	4	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

MEFV–CESC (OS)

Open the CESC breakdown →